FolioLanternBeta
VKTXViking Therapeutics, Inc.

Greg Zante

Chief Financial Officer at Viking Therapeutics, Inc., as of Jul 29, 2026Sold $2.8M of stock in the past 12 months: 100% to cover taxes.

Updated Oct 16, 2026 from SEC filings · covers Oct 17, 2025 to Oct 16, 2026
85K
shares sold, past 12 months
3
days with sales
$1.9M
largest single day, Jan 5, 2026
1
company filed for

Share of stake sold and shares held at Viking Therapeutics, Inc. are being verified and not shown yet. Why

Selling by month

Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.

To cover taxesOne dollar scale for every month; the tallest bar is labeled
Oct 2025: $216K to cover taxesOctNovDecJan 2026: $1.9M to cover taxes$1.9MJanFebMarAprMayJunJul 2026: $710K to cover taxesJulAugSepOct

Pattern

What the filings show, past 12 months. Nothing here rates or predicts.

Roles from filings

Every company we track where this person has filed, newest filing first.

CompanyTitleFirst filingLatest filing
Viking Therapeutics, Inc. (VKTX)Chief Financial OfficerJan 6, 2021Jul 29, 2026

Recent filings

The last 5 days with transactions, newest first, one line per trade date. Each number links to an SEC filing.

This page shows only what this person reported on SEC ownership filings. See the methodology. Spotted something wrong? Report an error.